DEXYANE MeD

Palpebral

Medical device

  • Treats and limits the recurrence of eczema lesions.
  • Treats and limits the recurrence of eczema lesions. Tested under dermatological control.
  • Anti-eczema
    • Palpebral
    • Palpebral
    • Palpebral

      DEXYANE MeD

      Palpebral

      Medical device Soothes itchiness - Treats eczema lesions - Decongests - Soothes

      A medical device that treats atopic or contact eczema on the eyelids.

      • Treats and limits the recurrence of eczema lesions.
      • Treats and limits the recurrence of eczema lesions. Tested under dermatological control.

      Usable by Infants - Children - Family - Adults

      Age From 3 month(s)

      Suitable Eyelids

      Skin type Eyelid eczema

      Need Anti-eczema

      Made in France

      DEXYANE MeD Palpebral is a medical device* for treating localised atopic or contact eczema on the eyelids.
      Its formula, specially adapted to respect the delicate skin of the eyelids, acts as an ultra-hydrating dressing.
      It instantly soothes itching sensations¹ and reduces burning sensations¹.
      DEXYANE MeD Palpebral restores the skin barrier and corrects dryness.
      It can be used as a stand-alone treatment, in combination with, or as a follow-up to topical corticosteroids.
      Clinically proven effectiveness.

      Benefit

      DEXYANE MeD Palpébral relieves inflammatory eczema lesions on the eyelids.

      Benefits

      • SOOTHES itching
      • COMFORTS immediately and decongests
      • LIMITS the recurrence of eczema lesions

      Product scent

      Fragrance-free

      Packaging that does not contain recycled material
      Fully recyclable packaging

      *DEXYANE MeD Palpebral is a medical device, a regulated health product which carries, in accordance with this regulation, the CE mark. Carefully read the instruction leaflet provided. Do not use if pregnant or breastfeeding. Avoid direct contact with the eyes. Age 3 months and up. Manufacturer : Pierre Fabre Medical Devices.

      Application

      Frequency of use

      1 to 2 times a day

      • Apply a thin layer directly to inflammatory eczema lesions on the eyelids with a clean finger, avoiding contact with the eye
      • For external use
      • Use as a stand-alone treatment, in combination with, or as a follow-up to topical corticosteroids
      • Once or twice a week
      • Do not use if you are allergic to any of the ingredients
      • If you experience an allergic reaction, consult a doctor
      • Due to a lack of data, use if pregnant or breastfeeding is not recommended
      • Keep out of the reach of children
      • Avoid direct contact with the eyes
      • Close the tube tightly after use
      • Do not use the product if the tube is damaged
      • If you experience any side effects as a result of using the product, seek medical advice
      • Can be used on skin damaged by cancer treatments

      Ingredients

      WATER (AQUA). GLYCERIN. CAPRYLIC/CAPRIC TRIGLYCERIDE. BUTYLENE GLYCOL. POLYSORBATE 60. GLYCERYL STEARATE. BUTYROSPERMUM PARKII (SHEA) BUTTER (BUTYROSPERMUM PARKII BUTTER). PROPYLENE GLYCOL. BEESWAX (CERA ALBA). PEG-100 STEARATE. 10-HYDROXYDECENOIC ACID. CAPRYLYL GLYCOL. CETYL ALCOHOL. CITRIC ACID. DISODIUM EDTA. GLYCYRRHETINIC ACID. POLYACRYLATE-13. POLYISOBUTENE. POLYSORBATE 20. SCLEROTIUM GUM. SORBITAN ISOSTEARATE

      The consumer is advised to systematically check the composition of the product before purchasing it.

      Results

      • Immediately¹ after application : itching reduced
      • After 3 days¹ : significant improvement and even complete disappearance of clinical signs, particularly burning sensations

        ¹Result of a clinical study conducted on 33 adults from 19-70 years old with mild to moderate atopic or contact eyelid eczema. DEXYANE MeD Palpebral was applied twice a day to the eyelids for 22 days. The clinical severity score (including itching, burning, tightness, etc.) from 0 to 9, immediately after 3 days of application, was compared to the pre-application scores. Immediately, the itching score significantly decreased, and the burning score improved by day 3. The overall development of lesions was evaluated by the PGA score on a 5-point scale : 0 (aggravation) to 4 (completely healed); after 3 days of application, the majority of patients felt an improvement. PFDC study PRM03-F-197_V3_AN. 03/2019. 98-104, 108.

        We recommend

          Loading...